{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04716231",
            "orgStudyIdInfo": {
                "id": "VT-001-0050"
            },
            "organization": {
                "fullName": "Vera Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Atacicept in Subjects With IgA Nephropathy",
            "officialTitle": "A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)",
            "acronym": "ORIGIN 3",
            "therapeuticArea": [
                "Nephrology and Renal Diseases",
                "Other"
            ],
            "study": "atacicept-in-subjects-with-iga-nephropathy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-11",
            "studyFirstSubmitQcDate": "2021-01-15",
            "studyFirstPostDateStruct": {
                "date": "2021-01-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vera Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)",
            "detailedDescription": "This is a multi-part study comprising of the original Phase 2b study (active, no longer recruiting) and the addition of a separate pivotal Phase 3 study (active, recruiting).\n\nAfter the completion of the primary results for the Ph 2b dose ranging study, the pivotal study (active, recruiting) will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized."
        },
        "conditionsModule": {
            "conditions": [
                "IgA Nephropathy",
                "Berger Disease"
            ],
            "keywords": [
                "Berger Disease",
                "Berger's Disease",
                "IGA Glomerulonephritis",
                "IGA Nephropathy",
                "Iga Nephropathy 1",
                "Immunoglobulin A Nephropathy Nephritis",
                "IGA Type Nephropathy, IGA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 376,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Atacicept Dose 150mg",
                    "type": "EXPERIMENTAL",
                    "description": "Atacicept 150mg once weekly subcutaneous (SC) injections",
                    "interventionNames": [
                        "Biological: Atacicept"
                    ]
                },
                {
                    "label": "Placebo to match Atacicept (Part C/D)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo to match Atacicept once weekly subcutaneous (SC) injection",
                    "interventionNames": [
                        "Other: Placebo to match Atacicept"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Atacicept",
                    "description": "Once weekly subcutaneous (SC) injections by prefilled syringe",
                    "armGroupLabels": [
                        "Atacicept Dose 150mg"
                    ],
                    "otherNames": [
                        "VT-001"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo to match Atacicept",
                    "description": "Once weekly subcutaneous (SC) injections by prefilled syringe",
                    "armGroupLabels": [
                        "Placebo to match Atacicept (Part C/D)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from baseline in urine protein to creatinine ratio (UPCR)",
                    "description": "UPCR based on 24 hour urine collection",
                    "timeFrame": "36 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Annualized rate of change in estimated glomerular filtration rate (eGFR)",
                    "description": "eGFR calculated by CKD-EPI formula",
                    "timeFrame": "52 and 104 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Must have the ability to understand and sign a written informed consent form\n* Male or female of \u226518 years of age\n* Total urine protein excretion \u22651.0 g per 24-hour or urine protein to creatinine ratio (UPCR) \u22651.0 mg/mg based on a 24-hour urine sample during the Screening Period\n* Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years\n* eGFR \u2265 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n* On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum labeled or tolerated dose at Screening\n* Systolic blood pressure \u2264150 mmHg and diastolic blood pressure \u226490 mmHg\n\nKey Exclusion Criteria:\n\n* IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura), systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis\n* Total urine protein excretion \u2265 5g per 24-hour or urine protein to creatinine ratio (UPCR) \u2265 5 mg/mg based on a 24-hour urine sample during the Screening Period\n* Evidence of rapidly progressive glomerulonephritis (loss of \u2265 50% of eGFR within 3 months of screening)\n* Evidence of nephrotic syndrome within 6 months of screening (serum albumin \\<30g/L in association with UPCR \\>3.5 mg/mg\n* Renal or other organ transplantation prior to, or expected during the study\n* Concomitant chronic renal disease in addition to IgAN\n* Uncontrolled diabetes, defined as hemoglobin-A1c (HbA1c) \\>7.5% at screening\n* History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of active TB determined by a positive Quantiferon test\n* Participation in the Phase 2b (Parts A and B) study or any previous treatment with atacicept",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vera Therapeutics, Inc. Clinical Trials Information",
                    "role": "CONTACT",
                    "phone": "650-770-0077",
                    "email": "clinicaltrials@veratx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rubeen Israni",
                    "affiliation": "Sr. Director, Clinical Development",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "ORIGIN 3 Global Site Contact Information",
                    "status": "RECRUITING",
                    "city": "Brisbane",
                    "state": "California",
                    "zip": "94005",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brisbane, California",
                            "role": "CONTACT",
                            "phone": "650-770-0077",
                            "email": "clinicaltrials@veratx.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.68077,
                        "lon": -122.39997
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Vera Therapeutics, Inc Company Website",
                    "url": "http://www.veratx.com"
                },
                {
                    "label": "ORIGIN 3 Study Website",
                    "url": "https://www.theoriginiganstudy.com/origin3-study"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Australia",
                "Belgium",
                "Canada",
                "Czechia",
                "Germany",
                "Greece",
                "India",
                "Korea, Republic of",
                "Malaysia",
                "Poland",
                "Turkey",
                "United Kingdom"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000005922",
                    "term": "Glomerulonephritis, IGA"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005921",
                    "term": "Glomerulonephritis"
                },
                {
                    "id": "D000009393",
                    "term": "Nephritis"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "asFound": "Nephropathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9032",
                    "name": "Glomerulonephritis, IGA",
                    "asFound": "IgA Nephropathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9031",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12338",
                    "name": "Nephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3008",
                    "name": "IgA Nephropathy",
                    "asFound": "IgA Nephropathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2525",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M10118",
                    "name": "Immunoglobulin A",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}